Veracyte

Meridian CEO Jack Kenny said the firm needs to develop a new MDx platform, while Genapsys resurfaced with an update on its portable sequencing platform.

Veracyte plans to launch a new version of its Percepta test and present data for a nasal swab lung cancer diagnostic this year.

The index fell more than 11 percent in December, underperforming the Dow and the Nasdaq, but performing on par with the Nasdaq Biotechnology Index.

The company said that 20 medical centers in the US are now offering the Envisia Genomic Classifier through an early-access program begun in May.

After six straight months of gains, the index saw a sharp drop in October that even positive earnings news could not stave off.

The firm said genomic testing volume rose 23 percent year over year, and raised its revenue guidance for full-year 2018.

The company's shares grew 28 percent in September after it terminated a licensing deal with BioMérieux and regained control of certain intellectual property.

Veracyte said that the draft policy is open to a 45-day comment period and could potentially go into effect in early 2019.

The company said proceeds will be used for working capital, and may also be used to acquire or invest in complementary businesses or technologies.